

Subject: FW: New York State mAb updates

Date: Monday, December 13, 2021 at 5:57:14 PM Eastern Standard Time

From: Bastinelli, Kate

From: COVID-19 Therapeutics <C19THERAPEUTICS-L@LISTSERV.HEALTH.STATE.NY.US> on behalf of doh.sm.COVID19therapeutics <000000e70387b1f8-dmarc-request@LISTSERV.HEALTH.STATE.NY.US>

Sent: Friday, December 10, 2021 1:45 PM

To: C19THERAPEUTICS-L@LISTSERV.HEALTH.STATE.NY.US <C19THERAPEUTICS-L@LISTSERV.HEALTH.STATE.NY.US>

Subject: New York State mAb updates

Hello,

On Wednesday, the Food and Drug Administration (FDA) granted Emergency Use Authorization (EUA) for the AstraZeneca product EVUSHEILD.

Due to high demand and low initial supply, a focused pilot program is being established for the initial distribution. We will **not** be taking requests for this therapeutic. It is anticipated that additional supply will be released in the future and at that time, more information will be made available for how to receive this product.

As it relates to current monoclonal antibody distribution (e.g. Regeneron, BAM/ETE...), supply from the federal government continues to decline while demand increases. For the first time we were not able to meet the demand for BAM/ETE requests this week. We have no additional product to allocate. We will not know until Monday what our allotment will be from the federal government for the next cycle, and we cannot guarantee that sites will receive the same allocations as they have previously.

In the last 2 weeks we received over 32,000 requests (20,000 in this week alone) for the [13,006 courses](#) we had available to allocate this cycle (November 29 - December 12). We are encouraging provider sites to follow the [NIH guidelines](#) for the prioritization of patient populations and treatment over Post-exposure prophylaxis (PEP) as there is still a nationwide shortage and cases are increasing throughout many regions of the state.

To unsubscribe from C19THERAPEUTICS-L, send email to:
C19THERAPEUTICS-L-signoff-request@listserv.health.state.ny.us